Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

被引：0
|
作者：
Fizazi, K. [1 ]
Luz, M. [2 ]
Ulys, A. [3 ]
Ortiz, J. [4 ]
Srinivasan, S. [5 ]
Kurland, E. [6 ]
Shore, N. D. [7 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France
[2] Hosp Erasto Gaertner, Dept Urol, Curitiba, Parana, Brazil
[3] Vilnius Univ, Inst Oncol, Vilnius, Lithuania
[4] Bayer HealthCare, Dept Med Affairs, Whippany, NJ USA
[5] Bayer HealthCare, Dept Stat, Whippany, NJ USA
[6] Bayer HealthCare, Clin Dev, Whippany, NJ USA
[7] Carolina Urol Res Ctr & Genesis Care, Dept Urol, Atlant Urol, Myrtle Beach, SC USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A1193
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
    Yildizhan, Mehmet
    Gemalmaz, Hakan
    Ertek, Mehmet Sirin
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (02): : 120 - 127
  • [42] Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Altavilla, Amelia
    Casadei, Chiara
    Lolli, Cristian
    Menna, Cecilia
    Ravaglia, Giorgia
    Gurioli, Giorgia
    Farolfi, Alberto
    Brighi, Nicole
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Schepisi, Giuseppe
    Rossi, Lorena
    Gargiulo, Stefania
    Lisotti, Ivana
    De Giorgi, Ugo
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2091 - 2099
  • [43] Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
    Boegemann, Martin
    Shore, Neal D.
    Smith, Matthew R.
    Tammela, Teuvo L. J.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Lebret, Thierry
    Schostak, Martin
    Verholen, Frank
    Le Berre, Marie-Aude
    Srinivasan, Shankar
    Ortiz, Jorge
    Mohamed, Ateesha F.
    Sarapohja, Toni
    Fizazi, Karim
    EUROPEAN UROLOGY, 2023, 83 (03) : 212 - 221
  • [44] Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
    Roumiguie, Mathieu
    Paoletti, Xavier
    Neuzillet, Yann
    Mathieu, Romain
    Vincendeau, Sebastien
    Kleinclauss, Francois
    Mejean, Arnaud
    Guy, Laurent
    Timsit, Marc Olivier
    Lebret, Thierry
    FUTURE ONCOLOGY, 2021, 17 (14) : 1811 - 1823
  • [45] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer (vol 380, pg 1235, 2019)
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (09): : 860 - 860
  • [46] Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation
    Mainwaring, P.
    Small, E.
    Uemura, H.
    Lee, J. Y.
    Pang, S-T.
    Marx, G.
    Kwon, T. G.
    Satoh, T.
    Bhaumik, A.
    Cheng, S.
    Londhe, A.
    Lopez-Gitlitz, A.
    Smith, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 68 - 68
  • [47] Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Halabi, Susan
    Jiang, Shan
    Terasawa, Emi
    Garcia-Horton, Viviana
    Ayyagari, Rajeev
    Waldeck, A. Reginald
    Shore, Neal
    JOURNAL OF UROLOGY, 2021, 206 (02): : 298 - 307
  • [48] Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2020, 22 (01) : 76 - 78
  • [49] EFFICACY AND SAFETY OF DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH AND WITHOUT PRIOR LOCAL THERAPY WITH RADICAL PROSTATECTOMY OR RADIOTHERAPY
    Siemens, David Robert
    Fizazi, Karim
    Shore, Neal D.
    Smith, Matthew R.
    Ortiz, Jorge
    Schmall, Anja
    Srinivasan, Shankar
    Verholen, Frank
    Saar, Matthias
    JOURNAL OF UROLOGY, 2022, 207 (05): : E451 - E451
  • [50] Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study
    Feng, Felix
    Thomas, Shibu
    Gormley, Michael
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Cheng, Shinta
    Ricci, Deborah S.
    Rooney, Brendan
    Mainwaring, Paul N.
    Olmos, David
    Saad, Fred
    Chowdhury, Simon
    Hadaschik, Boris
    Fishbane, Nick
    Davicioni, Elai
    Liu, Yang
    Small, Eric J.
    Smith, Matthew R.
    CANCER RESEARCH, 2019, 79 (13)
12345